Hank Mansbach

1.4k total citations · 1 hit paper
34 papers, 929 citations indexed

About

Hank Mansbach is a scholar working on Epidemiology, Molecular Biology and Physiology. According to data from OpenAlex, Hank Mansbach has authored 34 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Epidemiology, 15 papers in Molecular Biology and 9 papers in Physiology. Recurrent topics in Hank Mansbach's work include Fibroblast Growth Factor Research (15 papers), Liver Disease Diagnosis and Treatment (14 papers) and Diet, Metabolism, and Disease (5 papers). Hank Mansbach is often cited by papers focused on Fibroblast Growth Factor Research (15 papers), Liver Disease Diagnosis and Treatment (14 papers) and Diet, Metabolism, and Disease (5 papers). Hank Mansbach collaborates with scholars based in United States, Israel and United Kingdom. Hank Mansbach's co-authors include Maya Margalit, Cynthia L. Hartsfield, Rohit Loomba, Juan P. Frías, Germaine D. Agollah, Shibao Feng, Deepak L. Bhatt, Chris Webster, Andrew Dowson and Stewart J. Tepper and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of the American College of Cardiology.

In The Last Decade

Hank Mansbach

31 papers receiving 906 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

2023 271 citations Rohit Loomba, Arun J. Sanyal et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hank Mansbach United States	13	369	279	214	202	154	34	929
Joanne Topping United Kingdom	11	411 1.1×	196 0.7×	140 0.7×	48 0.2×	118 0.8×	18	1.2k
Pasquale Somma Italy	14	113 0.3×	299 1.1×	130 0.6×	218 1.1×	126 0.8×	17	980
R. Gasser Austria	23	230 0.6×	158 0.6×	450 2.1×	45 0.2×	77 0.5×	57	1.2k
P. Kaminsky France	19	88 0.2×	262 0.9×	63 0.3×	36 0.2×	159 1.0×	78	1.0k
Arve Dahl Norway	13	391 1.1×	253 0.9×	49 0.2×	69 0.3×	193 1.3×	23	997
Linda Webster Canada	10	158 0.4×	455 1.6×	104 0.5×	146 0.7×	243 1.6×	12	1.8k
Andrew J. Li United States	23	150 0.4×	237 0.8×	39 0.2×	121 0.6×	38 0.2×	42	1.5k
Kristel Vandormael United States	14	88 0.2×	297 1.1×	78 0.4×	175 0.9×	169 1.1×	20	2.4k
Katarzyna Ziemnicka Poland	20	234 0.6×	218 0.8×	451 2.1×	34 0.2×	128 0.8×	89	972
J M De Matias Spain	9	218 0.6×	155 0.6×	65 0.3×	52 0.3×	85 0.6×	14	713

Countries citing papers authored by Hank Mansbach

Since Specialization

Citations

This map shows the geographic impact of Hank Mansbach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hank Mansbach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hank Mansbach more than expected).

Fields of papers citing papers by Hank Mansbach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hank Mansbach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hank Mansbach. The network helps show where Hank Mansbach may publish in the future.

Co-authorship network of co-authors of Hank Mansbach

This figure shows the co-authorship network connecting the top 25 collaborators of Hank Mansbach. A scholar is included among the top collaborators of Hank Mansbach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hank Mansbach. Hank Mansbach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nordestgaard, Ask Tybjærg, Anne Tybjærg‐Hansen, Hank Mansbach, et al.. (2025). Target Populations for Novel Triglyceride-Lowering Therapies. Journal of the American College of Cardiology. 85(19). 1876–1897. 11 indexed citations

Bhatt, Deepak L., Stephen A. Harrison, Mildred D. Gottwald, et al.. (2024). Pegozafermin, a FGF21 Analog, for the Treatment of Non-alcoholic Steatohepatitis (NASH) Patients with F2/F3 Fibrosis. Metabolism. 153. 155873–155873.

Hartsfield, Cynthia L., Deepak L. Bhatt, Harold Bays, et al.. (2024). Study Design of a Phase 3 Randomized Controlled Trial Evaluating the Efficacy and Safety of Pegozafermin in Patients with Severe Hypertriglyceridemia. Journal of clinical lipidology. 18(4). e552–e553. 1 indexed citations

Loomba, Rohit, Manal F. Abdelmalek, Kris V. Kowdley, et al.. (2024). OS-118 Week 48 results from the phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis. Journal of Hepatology. 80. S72–S72.

Bhatt, Deepak L., Harold Bays, Michael Miller, et al.. (2023). The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nature Medicine. 29(7). 1782–1792. 66 indexed citations

Alkhouri, Naim, Donald J. Lazas, Rohit Loomba, et al.. (2023). Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy‐confirmed nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 58(10). 1005–1015. 8 indexed citations

Loomba, Rohit, Naim Alkhouri, Shibao Feng, et al.. (2023). Pegozafermin Improved Liver Histology, Liver-related Non-invasive Tests (NITs) and Metabolic Profiles in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis. Metabolism. 142. 155454–155454. 1 indexed citations

Rosenstock, Moti, Leo Tseng, Andrew L. Pierce, et al.. (2023). The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers. Journal of Pharmacology and Experimental Therapeutics. 387(2). 204–213. 16 indexed citations

Loomba, Rohit, Arun J. Sanyal, Kris V. Kowdley, et al.. (2023). Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. New England Journal of Medicine. 389(11). 998–1008. 271 indexed citations breakdown →

10.

Loomba, Rohit, Eric Lawitz, Juan P. Frías, et al.. (2022). Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. The Lancet. Gastroenterology & hepatology. 8(2). 120–132. 72 indexed citations

11.

Margalit, Maya, Chaoyin Chen, Leo Tseng, Moti Rosenstock, & Hank Mansbach. (2020). BIO89-100, a GlycoPEGylated FGF21 Analog, Improved Serum Lipids and Extended Half-Life in a Controlled Single Ascending Dose Trial in Healthy Subjects†. Journal of clinical lipidology. 14(4). 585–586. 4 indexed citations

12.

Rosenstock, Moti, et al.. (2020). BIO89-100, a novel glycopegylated FGF21 analog, reduces body weight and fat mass in naive CD-1 mice through an increase in energy expenditure despite an increase in food consumption. Journal of Hepatology. 73. S452–S452. 1 indexed citations

13.

Pierce, Andrew L., Moti Rosenstock, Maya Margalit, & Hank Mansbach. (2020). BIO89-100, a novel glycoPEGylated FGF21 Analog, Demonstrates Triglyceride Reduction and Broad Metabolic Effects in Spontaneously Diabetic Obese Cynomolgus Monkeys. Journal of clinical lipidology. 14(4). 584–585. 2 indexed citations

14.

Alumkal, Joshi J., Simon Chowdhury, Yohann Loriot, et al.. (2017). Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clinical Genitourinary Cancer. 15(5). 610–617.e3. 24 indexed citations

15.

Pogoryelova, Oksana, Hank Mansbach, Zohar Argov, et al.. (2017). Phenotypic stratification and genotype–phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: First report from the GNE myopathy Disease Monitoring Program, registry portion. Neuromuscular Disorders. 28(2). 158–168. 40 indexed citations

16.

Evans, Christopher P., Celestia S. Higano, Thomas E. Keane, et al.. (2016). The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. European Urology. 70(4). 675–683. 66 indexed citations

17.

Evans, Christopher P., Celestia S. Higano, Thomas E. Keane, et al.. (2014). PI-05 LATE-BREAKING ABSTRACT: THE PREVAIL STUDY: PRIMARY AND NON-VISCERAL / VISCERAL DISEASE SUBGROUP RESULTS FOR ENZALUTAMIDE-TREATED MEN WITH METASTATIC PROSTATE CANCER (MPC) THAT HAD PROGRESSED ON ADT. The Journal of Urology. 191(4S). 2 indexed citations

18.

Ivaturi, Vijay, Robert L. Kriel, Richard C. Brundage, et al.. (2012). Bioavailability of Intranasal vs. Rectal Diazepam. Epilepsy Research. 103(2-3). 254–261. 34 indexed citations

19.

Tepper, Stewart J., Carl Dahlöf, Andrew Dowson, et al.. (2004). Prevalence and Diagnosis of Migraine in Patients Consulting Their Physician With a Complaint of Headache: Data From the Landmark Study. Headache The Journal of Head and Face Pain. 44(9). 856–864. 162 indexed citations

20.

O’Quinn, Stephen, et al.. (2001). Reply: Evidence-Based Migraine Therapy. Cephalalgia. 21(9). 933–934. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact